QIBA PET Amyloid Biomarker Committee (BC) Call
8 September 2017 at 9:00 AM CT
Call Summary

In attendance:

<table>
<thead>
<tr>
<th>Dawn Matthews, MS, MBA (Co-Chair)</th>
<th>Paul Kinahan, PhD</th>
<th>John Sunderland, PhD</th>
<th>Joe Koudelik</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Smith, PhD (Co-Chair)</td>
<td>Adriaan Lammertsma, PhD</td>
<td>Jean-Luc Vanderheyden, PhD</td>
<td>Julie Lisiecki</td>
</tr>
<tr>
<td>Christopher Buckley, PhD</td>
<td>Nancy Obuchowski, PhD</td>
<td>Richard Wahl, MD, FACR</td>
<td></td>
</tr>
<tr>
<td>Anurag Gupta, PhD</td>
<td>Larry Pierce, PhD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RSNA**

Moderator: Dr. Smith

**PET Amyloid Poster for RSNA 2017:**

- Dr. Perlman reviewed the poster guidelines from Drs. Jackson and Guimaraes:
  - Organizational Structure Updates
  - Profile Development Status
  - Profile Impact/Implications for Clinical Trials and Patient Care (new focus for 2017)
  - Conformance Procedure Update
  - Groundwork Project Status/Results (optional)
    - Additional content to include would be an interim update regarding the IDEAS study
- The [2016 poster](#) was reviewed to determine what updates were needed
- A Quick Guide PDF brochure (or QR code) for the Profile was discussed for additional information to accompany the poster
  - This could help clinicians understand how to use the Profile for best practices in a clinical setting, as well as for clinical trials
- Ms. Matthews volunteered to be the poster coordinator
- Dr. Gupta offered to draft some text regarding how the Profile can best be used in the clinic
- The due date for a print-ready PowerPoint version to RSNA staff is **October 31st**

**DRO Update: (Drs. Pierce and Kinahan)**

- A set of 30 DROs in DICOM format are ready for beta-testing
- Dr. Pierce to work on a protocol for testing
  - Guidance may be available in the Profile appendix
- Considerations for DRO testing include:
  - What regions should be evaluated
  - What reference regions should be used
  - What measures should be evaluated
  - What should be in the final report
    - Dr. Obuchowski to be consulted
    - Dr. Buckley volunteered his help also
    - Dr. Koeppe and Centiloid group may also be consulted
- Dr. Kinahan to reach out to Dr. Nelson at MIMVista
- Volunteers who have agreed to test the DRO include: GE, Siemens and MIMVista
Profile Public Comment Updates:

- The Profile was released for public comment on June 1st; six comments have been received to-date
- Public Comment ends on September 15th
- Committee members intend to follow up personally with colleagues in order to solicit targeted feedback
- Updates regarding the volunteer contacts for sister organizations are as follows:
  - Alzheimer’s Association (Dr. Minoshima)
  - ADNI (Dr. Minoshima) – contacted
  - GAAIN (Dr. Minoshima)
  - FNIH (Drs. Wahl and Benzinger)
  - AFAR (Dr. Vanderheyden) – contacted
  - NIA (Drs. Wahl and Minoshima to contact Peter H. and others)
  - European and Japanese Initiatives (Dr. Boellaard)
  - Human Amyloid Imaging Group (Dr. Subramaniam and Ms. Matthews)
  - SNMMI Brain Council (already have Profile) – contacted
  - Keith Johnson, MGH, and Coordinator for Human Amyloid Imaging Meeting (Dr. Gupta) – contacted
  - AMYPAD European Consortium, will collect 6k scans/ 4 years (Dr. Lammerstma) – contacted
  - International Committee for MR and PET imagers (Dr. Benzinger)
  - Centiloid Working Group (Dr. Benzinger) – contacted
  - NIH Alzheimer’s Disease Centers Imaging Steering Committee (Dr. Benzinger) – contacted
  - Dominantly Inherited Alzheimer Network (DIAN) Imaging Committee – contacted
  - European Association of Nuclear Medicine (Neuro) – contacted
  - Julie Price (Ms. Matthews to contact after Sept 20th)
  - Dr. Buckley (aiding with the claim development)
  - Dr. Benzinger (received feedback)
  - GE Healthcare (received feedback)

- Boilerplate text regarding the value of the Amyloid Profile is needed when reaching out to sister organizations, to include:
  - Brief background with purpose and intended audience/use of the profile
  - What types of comments are requested, and suggested method for providing (e.g. the Excel spreadsheet)
- A strategy to triage and address comments is under development; co-chairs will review comment resolution spreadsheets from FDG-PET, SPECT, and MR Profiles and incorporate feedback

Open Issues requiring resolution include:

- Claim context and tolerance
- Conformance methodology (draft plan)
  - Region segmentation requirements
- Conformance testing (draft plan)
- Reference section

Action items:

- All: volunteer liaisons to solicit feedback for the Profile be submitted by the September 15th deadline
- Dr. Smith and Ms. Matthews to work on approach to resolve profile claim
- Drs. Kinahan, Pierce and team to complete DRO evaluation protocol for testing and feedback
- Ms. Matthews to draft poster and circulated prior to next BC call (10/13) for feedback
NM WebEx Schedule

<table>
<thead>
<tr>
<th>Date</th>
<th>Task Force</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/15</td>
<td>SPECT BC</td>
</tr>
<tr>
<td>9/29</td>
<td>NM Coordinating Ctte</td>
</tr>
<tr>
<td>10/6</td>
<td>FDG-PET BC</td>
</tr>
<tr>
<td>10/13</td>
<td>PET-Amyloid BC</td>
</tr>
<tr>
<td>10/20</td>
<td>SPECT BC</td>
</tr>
<tr>
<td>10/31</td>
<td>PPT print-ready posters due to RSNA</td>
</tr>
</tbody>
</table>

SPECT Task Forces

<table>
<thead>
<tr>
<th>Date</th>
<th>Task Force</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/3</td>
<td>I-123 Profile Comment Resolution</td>
</tr>
<tr>
<td>10/10</td>
<td>TC 99m Profile Development</td>
</tr>
</tbody>
</table>

SAVE-THE-DATE:

QIBA Working Meeting at RSNA 2017 | Wednesday, November 29, 2:30-6 pm – Lakeside Center, McCormick Place